Published in Adv Ther on March 17, 2016
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf (2007) 11.76
Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med (2005) 8.65
INTRAOCULAR PRESSURE RESPONSE TO TOPICAL CORTICOSTEROIDS. Invest Ophthalmol (1965) 2.39
STATISTICAL ATTRIBUTES OF THE STEROID HYPERTENSIVE RESPONSE IN THE CLINICALLY NORMAL EYE. I. THE DEMONSTRATION OF THREE LEVELS OF RESPONSE. Invest Ophthalmol (1965) 2.16
Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg (2012) 2.08
Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond) (2006) 1.88
Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol (1999) 1.73
Corticosteroid effects on cell signalling. Eur Respir J (2006) 1.63
Locally administered ocular corticosteroids: benefits and risks. Drug Saf (2002) 1.50
A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol (2004) 1.39
Steroid-induced iatrogenic glaucoma. Ophthalmic Res (2011) 1.27
Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol (1993) 1.18
Corticosteroids and glaucoma risk. Drugs Aging (1999) 1.13
Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea (2008) 1.08
Marked intraocular pressure response to instillation of corticosteroids in children. Am J Ophthalmol (1991) 1.03
Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. J Cataract Refract Surg (1998) 1.03
Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens (2004) 1.02
Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam (2012) 1.02
Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther (2010) 1.01
Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J (2005) 1.01
Ocular-hypertensive response to topical steroids in children. Ophthalmology (1997) 1.00
Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol (1975) 0.99
Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma (1998) 0.99
A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. Ophthalmology (1998) 0.98
The core mechanism of dry eye disease is inflammation. Eye Contact Lens (2014) 0.98
Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin (2008) 0.95
Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther (2013) 0.95
Visual loss caused by corticosteroid-induced glaucoma: how to avoid it. Retina (2009) 0.95
Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol (2008) 0.95
Dry eye: an inflammatory ocular disease. J Ophthalmic Vis Res (2014) 0.95
A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol (1997) 0.94
A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol (1997) 0.93
Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res (1991) 0.92
Long-Term Outcome of Treatment with Topical Corticosteroids for Severe Dry Eye Associated with Sjögren's Syndrome. Chonnam Med J (2015) 0.92
Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol (2012) 0.92
Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea (2009) 0.92
Glucocorticoid receptor represses proinflammatory genes at distinct steps of the transcription cycle. Proc Natl Acad Sci U S A (2013) 0.91
Iatrogenic glaucoma secondary to medications. Am J Med (2010) 0.91
A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol (1998) 0.91
An update on the surgical management of pterygium and the role of loteprednol etabonate ointment. Clin Ophthalmol (2014) 0.91
A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology (1999) 0.91
Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol (2011) 0.90
Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens (2014) 0.90
Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. Clin Ophthalmol (2012) 0.89
Corticosteroid-induced glaucoma. Int Ophthalmol Clin (1993) 0.89
Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study. J Cataract Refract Surg (2002) 0.89
Steroid-induced intraocular pressure elevation or glaucoma after penetrating keratoplasty in patients with keratoconus or Fuchs dystrophy. Cornea (2009) 0.88
Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg (2012) 0.88
A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Curr Med Res Opin (2012) 0.88
Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol (1991) 0.88
The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep (2002) 0.87
A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J (1997) 0.87
Use of loteprednol for routine prophylaxis after photorefractive keratectomy. Clin Ophthalmol (2012) 0.86
Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety. Jpn J Ophthalmol (2012) 0.86
Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis. Adv Ther (2007) 0.86
Intraocular pressure response to corticosteroids in children. Br J Ophthalmol (1980) 0.85
Corneal Confocal Microscopy in Dry Eye Treated with Corticosteroids. Optom Vis Sci (2015) 0.84
Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. Clin Ophthalmol (2013) 0.82
A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy. J Ocul Pharmacol Ther (2015) 0.82
Risk factors for steroid response among cataract patients. J Cataract Refract Surg (2011) 0.82
Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatr Drugs (2012) 0.82
Design of novel soft corticosteroids. Curr Probl Dermatol (1993) 0.81
Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Curr Opin Allergy Clin Immunol (2010) 0.81
Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial. Cornea (2015) 0.78
A Prospective, Open-label Study to Compare the Efficacy and the Safety of Topical Loteprednol Etabonate and Topical Flurbiprofen Sodium in Patients with Post-Operative Inflammation after Cataract Extraction. J Clin Diagn Res (2012) 0.78
Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. Am J Ophthalmol (2014) 0.78
Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone. Am J Ophthalmol (2007) 0.78
A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery. Clin Ophthalmol (2015) 0.76
Steroid-induced ocular hypertension with loteprednol etabonate 0.2%--a case report. Optometry (2011) 0.76
Designing safer ophthalmic drugs by soft drug approaches. J Ocul Pharmacol (1994) 0.75